You keep concentrating on the finacial information that was missing. Listen to the conference call again. This was just one aspect of the FDA response that puzzled him. He said that there were also other reasons that he did not want to share. He did say, however, that they were not problems with the machine itself.
These reasons, whatever they are, were discussed with the consultants and, apparently, are being addressed in the new submission.